Immune checkpoint inhibitor‐associated central nervous system autoimmunity
European Journal of Neurology · 2023
DOI: 10.1111/ene.15835 ↗At a glance
Journal article in European Journal of Neurology, 2023. Written by Cristina Valencia-Sanchez and 6 co-authors. Institution: Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA. Major MEDLINE topics: Neoplasms, Encephalitis. Cited 31 times so far (Crossref); 32 references. Funded by: NINDS NIH HHS.
Abstract (original language)
Background and purpose Outcome and rechallenge data on central nervous system (CNS) autoimmunity triggered by immune checkpoint inhibitors (ICIs) are limited. We aim to describe a large series of patients with ICI‐triggered CNS autoimmunity, and to compare these patients with spontaneous paraneoplastic syndromes (PNS).
Methods
We retrospectively reviewed Mayo Clinic patients with ICI‐triggered CNS autoimmunity (February 2015–June 2021). Clinical characteristics were compared to spontaneous PNS patients (with antineuronal nuclear antibody [ANNA]‐1 or anti‐Hu neurological autoimmunity, and/or neuroendocrine tumors [NET]) evaluated within the same period.
Results
Thirty‐one patients were included (55% female, median age = 63 years, range = 39–76). Median time from ICI initiation was 3.65 months (range = 0.8–44.5). The most common associated malignancies were melanoma and small cell lung cancer. CNS manifestations included encephalitis ( n = 16), meningoencephalitis ( n = 8), cerebellar ataxia ( n = 4), demyelinating syndrome ( n = 2), and myelopathy ( n = 1). Magnetic resonance imaging was abnormal in 62%. Cerebrospinal fluid was inflammatory in 70%. Neural autoantibodies were identified in 47%, more frequently in patients with NET ( p = 0.046). ICI was discontinued in 97%; 90% received immunosuppressive treatment. After median 6.8 months follow‐up (range = 0.7–46), 39% had unfavorable outcomes (grade ≥ 3). This was associated with higher severity degree at onset, shorter period from ICI to neurological symptom onset, and encephalitis. Four patients were rechallenged with ICI, and one relapsed. Patients with NET and with ANNA‐1 ICI‐triggered CNS autoimmunity had associated peripheral nervous system manifestations more frequently than their spontaneous counterparts ( p = 0.007 and p = 0.028, respectively).
Conclusions
One third of ICI‐related CNS autoimmunity patients have unfavorable outcomes. Relapses may occur after ICI rechallenge. Neural autoantibodies are often present, more commonly in patients with NET.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.
- Department of Medical, Surgical, and Experimental Sciences, University of Sassari, Sassari, Italy.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
- Center of Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID profiles: Cristina Valencia-Sanchez, Eoin P Flanagan, Sean J Pittock, Anastasia Zekeridou
Funding
- NINDS NIH HHS
Cite
APA
Valencia-Sanchez, C., Sechi, E., Dubey, D., Flanagan, E. P., McKeon, A., Pittock, S. J., & Zekeridou, A. (2023). Immune checkpoint inhibitor‐associated central nervous system autoimmunity. European Journal of Neurology. https://doi.org/10.1111/ene.15835
Vancouver
Valencia-Sanchez C, Sechi E, Dubey D, Flanagan EP, McKeon A, Pittock SJ, et al. Immune checkpoint inhibitor‐associated central nervous system autoimmunity. European Journal of Neurology. 2023. doi:10.1111/ene.15835
BibTeX
@article{ValenciaSanchez2023,
author = {Valencia-Sanchez, Cristina and Sechi, Elia and Dubey, Divyanshu and Flanagan, Eoin P and McKeon, Andrew and Pittock, Sean J and Zekeridou, Anastasia},
title = {Immune checkpoint inhibitor‐associated central nervous system autoimmunity},
journal = {European Journal of Neurology},
year = {2023},
doi = {10.1111/ene.15835}
}
EUVIMED